USA Today

Breast Cancer Survival Up With Everolimus + Exemestane
Monthly Prescribing Reference
(HealthDay News) - Everolimus plus exemestane improves progression-free survival (PFS) for postmenopausal women with hormone-receptor (HR)-positive breast cancer; and pertuzumab plus trastuzumab plus docetaxel improves PFS in human epidermal growth ...
mTOR inhibitors gaining favor for breast cancer treatmentEmory Health Now (blog)
SABCS: Updated BOLERO-2 Findings Confirm Efficacy of Everolimus Plus ExemestaneCancer Network
2 new drugs shown to slow breast cancer progressionBend Bulletin
Press TV
all 268 news articles »